CDMO– tag –
-
Strategic CDMO Partnerships Accelerate in Cell and Gene Therapy Market to Tackle Manufacturing and Cost Challenges
Contract Pharma USA Overview The burgeoning cell and gene therapy (CGT) market is increasingly relying on strategic CDMO partnerships to navigate complex manufacturing and cost challenges. Sponsors are actively seeking CDMOs with special... -
Made Scientific and Pluristyx Strengthen Alliance for iPSC Cell Therapy Manufacturing, Aiming to Reduce Rework and Accelerate Development Timelines
Made Scientific USA Overview Made Scientific and Pluristyx announced an enhanced strategic partnership to accelerate the development of iPSC-derived cell therapy candidates. This collaboration integrates Pluristyx's advanced iPSC platfor... -
AmMax Bio Licenses Lonza’s Conjugation and Linker-Payload Technologies for ADC Program AMB-104
The Pharma Letter USA Overview AmMax Bio announced a non-exclusive licensing agreement with Lonza, a leading CDMO, to utilize Lonza's conjugation and linker-payload technologies. This collaboration aims to support the development of AmMa... -
ENCell Secures US Clinical Manufacturing Contract for Ingenium Therapeutics’ NK Cell Therapy Gengleucel, Expanding Global CDMO Operations
Bio South Korea Overview ENCell, a South Korean CDMO specializing in cell and gene therapy, has signed an additional CMO contract with Ingenium Therapeutics for the manufacturing of clinical trial materials for its NK cell therapy candid... -
Alcami Expands CDMO Packaging Capabilities with Tjoapack Acquisition, Strengthening Cell and Gene Therapy Supply Chain
North Carolina Biotechnology Center USA Overview Alcami Corporation, a Contract Development and Manufacturing Organization (CDMO), has significantly expanded its packaging capabilities through the acquisition of global contract packaging... -
Made Scientific and Pluristyx Form Strategic Partnership to Integrate iPSC Technology and Expand Cell Therapy Manufacturing CDMO Services
BioPharm International USA Overview Made Scientific announced a strategic partnership with Pluristyx, an iPSC technology platform provider, to integrate iPSC technology into its cell therapy CDMO services. This collaboration will provide... -
FUJIFILM Cellular Dynamics Opens New iPSC Manufacturing Facility and Reorganizes Life Sciences Leadership to Accelerate Cell Therapy and iPSC Business Expansion
FUJIFILM Cellular Dynamics / Indian Pharma Post Japan Overview FUJIFILM Cellular Dynamics announced the opening of its new headquarters and iPSC development and manufacturing facility in Madison, tripling its iPSC-based research product ... -
Lonza Unveils Enhanced DNA-to-IND Biologics Manufacturing Offering with 6-Month Timelines, Introducing GS Ori-Go™
PharmaSource Switzerland Overview Lonza has announced an enhanced 'DNA-to-IND' offering for biologics, aiming to achieve IND-readiness for monoclonal antibody programs in as little as six months. This accelerated timeline is supported by... -
Fujifilm Diosynth Biotechnologies Strengthens Technological Leadership in Cell Culture, Microbial Fermentation, Viral Vectors, and Cell Therapy Manufacturing
MabDesign France Overview Fujifilm Diosynth Biotechnologies is focused on combining its technological leadership with cGMP manufacturing facilities across key areas: cell culture, microbial fermentation, viral vectors, and cell therapy. ... -
ENCell Secures US Clinical Manufacturing Contract for Ingenium’s AML-Targeting NK Cell Therapy, ‘gengleucel’
KBR South Korea Overview ENCell, a CDMO specializing in cell and gene therapies, has secured a manufacturing contract for Ingenium Therapeutics' allogeneic NK cell therapy candidate, 'gengleucel,' for U.S. clinical trials. This therapy t...
